Aspire Biopharma (ASBP) announced a strategic partnership with Microsize. Aspire has engaged Microsize to accelerate the development of a novel sublingual powder formulation of alprazolam, the active pharmaceutical ingredientI in the widely prescribed anti-anxiety medication Xanax.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASBP:
- Aspire Biopharma’s Buzz Bomb announces expansion of social media footprint
- Aspire Biopharma regains compliance with Nasdaq listing requirements
- Aspire Biopharma’s Buzz Bomb names ChicExecs as PR agency of record
- Aspire Biopharma files to sell 159.1M shares of common stock for holders
- Aspire Biopharma files provisional patent application for Meclizine formulation